PTCISB/08x (08-03)
Approved for use through 07/31/0006 ONG 0651-0001
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMS control number.

Under the Paperwork Reduction Act of 1995, no persons are req Application Number

	Application (tulliber			
	Filing Date		2006-05-11	
INFORMATION DISCLOSURE	First Named Inventor Karl S		SCHERMANZ	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit			
not for capillosion and of or it may	Examiner Name			
	Attorney Docket Numb	er	16785 1	

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Da	ite	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines wher int Passages or Rele s Appear	
	1	4221768		1980-09-	-09	Inoue et al				
	2	4466947		1984-08-	-21	Imanari et al				
	3	4719192		1988-01-	-12	Schneider et a	4			
	4	5300472		1994-04	-05	Brand et al				
If you wis	h to a	dd additional U.S. Pater							Add	
			U.S.P	ATENT A	APPLIC	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publicati Date	ion	Name of Patentee or Applicant		Releva	Columns,Lines wher int Passages or Rele s Appear	
	1									
If you wis	h to a	d additional U.S. Publi:	shed Ap	plication	citation	information p	lease click the Ad	d button	Add	
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Ts

Application Number Filing Date 2006-05-11 INFORMATION DISCLOSURE First Named Inventor Karl SCHERMANZ STATEMENT BY APPLICANT Art I Init (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 16785 1

	1	11216361	JP		1999-08-10	Toshiba Corp		
	2	54052691	JP		1979-04-25	Nippon Steel Corp		
	3	2149680	GB	A	1985-06-19	Nippon Shokubai Kagaku Kogyo Co. Ltd		
	4	0787521	EP	A1	1997-08-06	Ebara Corporation; Mitsubish Chemical Corporation		
	5	1430730	GB		1976-04-07	Mitsubishi Chemical Industries Ltd.		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								

NON-PATENT LITERATURE DOCUMENTS Remove include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite Т5 (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), Initials* No publisher, city and/or country where published.

you wish to add additional non-patent literature document citation information please click the Add button	Add
EXAMINER SIGNATURE	

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature Date Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO. Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached

Application Number Filing Date 2006-05-11 Filing Date 12006-05-11 Filing Date

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement was called the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/R. Burns Israelsen/	Date (YYYY-MM-DD)	2006-05-11
Name/Print	R. Burns Israelsen	Registration Number	42685

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.